Thuja Capital

Meet Eline van Beest, Operational Partner at Thuja. Eline started her entrepreneurial journey in 2009 when she founded Nightbalance, a spin-off of TU-Delft which developed a new therapy for sleep apnea, and which was acquired in 2018 by Philips. Currently Eline is the CEO of Hybridize Therapeutics, Operational Partner at Thuja and serves of numerous Boards and investment committees. Eline skillfully juggles entrepreneurship, family life and and all her many positions. Click on the link to read full interview: https://lnkd.in/eRC8VQKu

Welcome on board Stanton Rowe

We are delighted to share Thuja's 2023 Impact & ESG Annual Report!   Thuja invests exclusively in companies that offer solutions to high unmet medical needs, expected to have a major impact on human health through increasing healthy life expectancy, improving quailty of life and/or reducing health care costs. Here we report on the expected impact of our portfolio companies, based on our internally developed impact framework, along with our additionality as an early-stage hands-on investor (at the level of our portfolio companies and on the wider innovation ecosystem). In addition, we report on our approach to measuring and managing ESG-related risks and opportunities material to our portfolio, as we believe this is key to creating sustainable business and driving value.   2023 was the second year in which we implemented our impact and ESG approach for the Thuja Capital Healthcare Fund III portfolio. Whilst our approach to impact and ESG is continually evolving, we are delighted to see the strength and robustness of our approach as it is translated into action.   We are curious to learn what you think and would be keen to receive feedback.   You can read the full report here: https://lnkd.in/eQ7ixVxY Eleanor Price, Lisanne Blauw, Michel Briejer

Thank you for the shoutout! 🙌  We're thrilled to be a Bronze Sponsor and excited to support Europe's brightest innovators in the healthtech space. At Thuja Capital, we’re always on the lookout for disruptive solutions to address significant unmet medical needs.   If you’ve got an idea that’s ready to transform healthcare, don’t miss your chance to pitch to Thuja and other investors – apply before October 20th! (link in post 👇 )    Looking forward to seeing everyone in Bruges this December! 🎉

Congrats to Thuja portfolio company Pan Cancer T for their high-impact publication in Cancer Discovery! The article highlights the team's innovative approach, which led to the idenfication of Ropporin-1 (ROPN1) as a novel target for T-cell therapies for cancers of high unmet medical need, notably triple negative breast cancer (TNBC) and melanoma. The paper showcases the company's compelling preclinical data on the safety and efficacy of their lead T-cell receptor (TCR) T-cell product. Exciting developments ahead! To learn more: https://lnkd.in/e7v7Gkx9 #Immunotherapy #TCellTherapy #TNBC #Melanoma #VentureCapital

Congratulations to Hans Preusting and the Synerkine Pharma team on receiving European Orphan Drug Designation for SK-01 to treat Complex Regional Pain Syndrome (CRPS). This is an important milestone in Synerkine's journey towards developing disease-modifying treatments for patients living with severe and debilitating pain.

Congrats to portfolio company Pan Cancer T on their €4.25M seed extension! "This financing round enables us to advance our lead product toward the clinic, offering new hope for patients with triple negative breast cancer," shares Pan Cancer T CEO, Rachel Abbott. We also extend a warm welcome to new investor, InnovationQuarter, and are pleased to continue supporting Pan Cancer T's ambition to accelerate next-generation T cell therapies alongside existing investors, Van Herk Ventures (Van Herk Groep), Swanbridge Capital, and Erasmus MC O&O Holding. #TCellTherapy #BreastCancer #VentureCapital

Today we are publishing our second Impact Story, this time of FundaMental Pharma. Our portfolio companies are developing innovations that are expected to generate positive healthcare impact once they reach patients. With these 2-pagers we aim to explain the potential healthcare impact of our portfolio companies in an easy-to-grasp way.    FundaMental Pharma is developing innovative medicines to fight neurodegeneration with an initial focus is on the development of drugs to treat ALS. If successful, FundaMental Pharma, is expected to have a major impact on the quality of life of patients with ALS and other neurodegenerative diseases. Read all about it below or on our website https://lnkd.in/eEH2JpWg, where all impact stories will be published. Keep an eye on our LinkedIn page for more Impact Stories to come.

We are pleased to share that AstriVax has entered Clinical phase with its novel vaccine platform technology. Congrats to Hanne Callewaert and the rest of the team on achieving this significant milestone. #venturecapital #biotech #infectiousdiseases #clinicalstage #Thujafamily

We are delighted to share that Thuja led the extension of Tacalyx’s seed financing!   Tacalyx GmbH is developing a pipeline of antibody-based therapies targeting TACAs (tumour-associated carbohydrate antigens), for the treatment of solid tumours.    We see excellent potential in the expertise and technology of Tacalyx in the emerging field of glycan biology, and are excited to support the team in the development of novel therapies for cancers with high unmet need.    We congratulate Peter Sondermann and the Tacalyx team on the successful closing of this round and look forward to working with co-investors Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, Idinvest/Eurazeo, HTGF | High-Tech Gründerfonds, coparion, Creathor Ventures, Max Planck Society (MPG).  Read the full press release on our website: https://lnkd.in/eXkTi2_y   #venturecapital #biotech #oncology